Grifols (GRFS) Operating Income (2010 - 2020)
Grifols' (GRFS) quarterly Operating Income came in at $1.0 billion in Q1 2020, up 7.09% YoY from $937.7 million in Q2 2019, and down 65.5% on a QoQ basis from $2.9 billion in Q4 2019.
Grifols (GRFS) Operating Income (2010 - 2020) Analysis & Trends
Grifols (GRFS) has 11 years of Operating Income data on file, last reported at $1.0 billion in Q1 2020.
- Quarterly Operating Income rose 7.09% year-over-year to $1.0 billion in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $5.1 billion (up 183.16% YoY) and the FY2025 annual result came in at $1.4 billion, up 13.59% from the prior year.
- Operating Income declined to $1.0 billion in Q1 2020, from $2.9 billion in the prior quarter.
- In the past five years, Operating Income ranged from a high of $2.9 billion in Q4 2019 to a low of $252.4 million in Q4 2018.
- A 5-year average of $655.0 million and a median of $312.3 million in 2018 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2018 — Operating Income tumbled 73.29% — and 2019, when it surged 1053.32%.
- Tracing GRFS's Operating Income over 5 years: stood at $488.8 million in 2016, then surged by 93.31% to $944.9 million in 2017, then plunged by 73.29% to $252.4 million in 2018, then surged by 1053.32% to $2.9 billion in 2019, then tumbled by 65.5% to $1.0 billion in 2020.
- The last three Operating Income figures came in at $1.0 billion (Q1 2020), $2.9 billion (Q4 2019), and $937.7 million (Q1 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 648.02 Bn | 627.27 Bn | 17.26 Bn | 7.14 Bn |
| 2 | AbbVie | 467.00 Bn | 460.43 Bn | 12.70 Bn | 6.43 Bn |
| 3 | Merck | 373.58 Bn | 366.43 Bn | 12.21 Bn | -584.00 Mn |
| 4 | Novartis Ag | 299.43 Bn | 291.74 Bn | 11.24 Bn | 4.75 Bn |
| 5 | Astrazeneca | 256.09 Bn | 251.19 Bn | 12.86 Bn | 3.16 Bn |
| 6 | Amgen | 235.35 Bn | 221.36 Bn | 7.24 Bn | 3.51 Bn |
| 7 | Gilead Sciences | 179.91 Bn | 176.73 Bn | 6.22 Bn | -10.39 Bn |
| 8 | Pfizer | 159.32 Bn | 147.62 Bn | 10.94 Bn | 4.27 Bn |
| 9 | Gsk | 104.91 Bn | 100.74 Bn | 8.24 Bn | 645.35 Mn |
| 10 | Grifols | 5.49 Bn | 4.49 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 1.00 Bn |
| Dec 31, 2019 | 2.91 Bn |
| Mar 31, 2019 | 937.75 Mn |
| Dec 31, 2018 | 252.39 Mn |
| Jun 30, 2018 | 312.31 Mn |
| Mar 31, 2018 | 300.50 Mn |
| Dec 31, 2017 | 944.89 Mn |
| Jun 30, 2017 | 313.51 Mn |
| Mar 31, 2017 | 269.23 Mn |
| Dec 31, 2016 | 488.79 Mn |
| Sep 30, 2016 | 267.29 Mn |
| Jun 30, 2016 | 257.31 Mn |
| Mar 31, 2016 | 255.35 Mn |
| Dec 31, 2015 | 787.01 Mn |
| Sep 30, 2015 | 275.09 Mn |
| Jun 30, 2015 | 258.96 Mn |
| Mar 31, 2015 | 267.09 Mn |
| Dec 31, 2014 | 1.07 Bn |
| Sep 30, 2014 | 283.89 Mn |
| Jun 30, 2014 | 560.67 Bn |